In another recent high-profile paper, it was shown that IDH1 mutation in leukemia cells caused MAPK activation, and targeting this pathway through CDK4/6 inhibitor Abemaciclib, more effectively inhibited proliferation in IDH mutant AML than in IDH wild-type AML [18, 19]. This evidence concerns the gene CDK4 and acute myeloid leukemia.